Baker McKenzie’s Jaspreet Takhar on the future of digital health solutions
What made you decide to specialise in life sciences law?
I specialise in advising on digital health solutions – that means advising on the regulation of health data, digital health solutions (including AI solutions, software and medical devices), as well as contracting in this space. I genuinely find the digital health space as exciting as it gets! The legal landscape is changing at breakneck speed, and I spend a few minutes every morning scanning for new regulations, new announcements and new guidance. Hot topics for legal developments include the regulation of AI, the European Health Data Space, and local laws on medical confidentiality. Continue reading “Rising stars: Jaspreet Takhar – ‘EU regulators are preparing an avalanche of new laws that are going to have a monumental impact on pharma and medtech’”
Dr Chris Boyle, counsel at Sidley, on the risks and opportunities facing the industry
What do you most enjoy about being a life sciences lawyer?
My passion for science led me to qualify and practice as a veterinary surgeon before I discovered that scientists and clinicians are uniquely placed to make a big impact in law, and I requalified as a life sciences lawyer. The best thing about being a life sciences lawyer is that I can harness my scientific interest and knowledge to serve clients on a far greater scale than I could in veterinary practice, to help them develop the health technologies and services of tomorrow. It is particularly helpful to ‘speak the same language’ when I am advising on matters that require interactions with healthcare professionals and regulators – for example it has proven key in assisting clients with NICE health technology assessments. Continue reading “Rising stars: Dr Chris Boyle – ‘AI is going to have a transformative impact on the life sciences industry’”
David Gibson, senior associate at McDermott Will & Emery
Why did you decide to specialise in life sciences law, and what’s the best thing about being a life sciences lawyer?
I find the subject matter fascinating, and I am genuinely curious about new technologies and medicines and how they can be used, shared and applied to improve healthcare for patients across the world. We are often involved in helping our clients with strategic projects and transactions, partnering with other organisations and bringing products to market and to scale – often across different jurisdictions. As a transactional and projects lawyer, I enjoy working with clients to bring the commercial, financing, regulatory and other legal elements together: it is an area of law that has a bit of everything! Continue reading “Rising stars: David Gibson – ‘There are so many great new technologies and medicines with potential to make a difference to populations and treatment pathways but key challenges remain in regulating them’”
China’s life sciences and healthcare (LS&H) industry underwent an unprecedented transformation in 2023 consisting of numerous challenges and opportunities. Within this year, BD transactions primarily included out-licensing of ex-China rights, China commercialisation partnering, asset acquisition and regaining drug product rights, which reflected the courage of China’s LS&H market players to proactively seek changes and rebuild corporate strategies in a quickly shifting market landscape.
Fangda Partners’ life sciences team remained active in advising on LS&H corporate transactions in 2023 and recent key deal highlights included (a) Hengrui Pharma (600276.SH)’s out-licensing partnership with Aiolos Bio to exploit the innovative anti-TSLP mAb (SHR-1905) outside of Greater China; (b) Kanghua Biological (300841.SZ)’s grant of exclusive rights to HilleVax for exploitation of recombinant hexavalent VLP norovirus vaccine outside of Greater China; (c) CStone Pharma (2616.HK)’s sale of the Tibsovo® (Ivosidenib) business, asset and goodwill thereof in Greater China and Singapore to Les Laboratoires Servier; and (d) a number of commercialisation arrangements entered into by multinational pharmaceutical companies with leading CSOs. Continue reading “Sponsored thought leadership: China life sciences – Transaction insights and notable industry trends”
1. What are the current regulatory frameworks governing the life sciences industry in China, and how have they evolved in recent years?
Legislation wise, the Drug Administration Law and its implementation rules are pivotal to the pharmaceutical sector, overseeing the entire lifecycle of chemical and biological products. For medical devices (including in-vitro diagnostics), the Regulations for the Supervision and Administration of Medical Devices form a fundamental framework. Continue reading “Sponsored Q&A: Fangda Partners”
The health sector in Portugal, which encompasses the pharmaceutical market, is a prominent and fast-evolving sector that has undergone significant growth in recent decades.
Sérvulo & Associados law firm is proud to have a highly specialised, experienced and well-balanced team in the life sciences field. The team covers all the main legal matters of the health and pharmaceutical industry, acting and providing guidance on a broad range of issues. These include patent trademark litigation within the pharmaceutical sector, but also advice on regulatory matters, data privacy for clinical research, and patient support programmers, as well as distribution and supply agreements to the industry. Continue reading “Sponsored thought leadership: Healthcare and pharmaceutical regulation in Portugal”